Cytokinetics gets an 'incremental' win for delayed heart drug
Cytokinetics’s aficamten is better than the standard of care in a heart muscle disease, the company said Tuesday. The development is positive, but with aficamten’s approval submission delayed, it will...
View ArticleArcturus to prioritize mRNA therapeutics in bid to boost rare disease programs
Arcturus Therapeutics is doubling down on mRNA technology. The biotech said Monday that it's prioritizing its experimental self-amplifying mRNA drugs, with a focus on programs for cystic fibrosis and a...
View ArticleSome generics, biosimilar drugmakers say they can withstand tariff impact
A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential pharma-specific tariffs due to their domestic production footprints and not...
View ArticleHHS issues guidance for third round of drug price negotiations
The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations under guidance that seeks to align with and improve transparency in the...
View ArticleCRISPR patent spat revived by federal appeals court ruling
An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a revolutionary gene editing technology. The US Court of Appeals for the...
View ArticleOmada Health joins the digital health IPO corral
On Friday afternoon, Ngai, Shelby and I dropped what we were doing when we saw Omada Health had filed to go public. Omada, the virtual chronic care provider, joins virtual ...
View ArticleAdvocacy groups and experts call for decade-long ban on germline editing
Cell and gene therapy advocacy organizations are jointly calling for a 10-year international moratorium on gene editing of the human germline. They say such use of gene editing comes with questionable...
View ArticleNovo turns to Septerna for oral obesity medicines in deal worth up to $2.2B
Novo Nordisk continues to sling obesity drug partnerships. Its latest biotech of choice is Septerna, which will help the Danish pharma make oral small molecules. Novo will give over $200 million in...
View ArticleGSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope
GSK will hand over $1.2 billion in upfront cash to license a closely-watched candidate for fatty liver disease from Boston Pharmaceuticals. The drug in question is Boston Pharma’s lead asset,...
View ArticleAbbVie doubles down on siRNA with $335M upfront bet on ADARx
After getting into siRNA work with its $1.4 billion acquisition of Aliada Therapeutics late last year, AbbVie is beefing up its presence in the hot subfield of genetic medicines. On Wednesday, AbbVie ...
View ArticleSK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M
Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics: SK, Carlyle offer more upfront cash to bluebird bio shareholders:...
View ArticleFDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer
The FDA approved a new antibody-drug conjugate from AbbVie on Wednesday to treat patients with certain kinds of lung cancer. Regulators granted accelerated approval to telisotuzumab vedotin in...
View ArticleSanofi touts $20B investment in US over five years
Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several pharma companies. The company said Wednesday that the investment includes...
View ArticleEx-FDA chief Robert Califf thinks RFK Jr.'s vaccine opinions are relevant
HHS Secretary Robert F. Kennedy Jr. told a House committee Wednesday morning that he believed his opinions on vaccines were “irrelevant,” prompting a rebuke from a former top US health official. The...
View ArticleRFK Jr. defends HHS staff cuts at two congressional hearings
HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and planned overhaul of the agency that’s expected to shrink the workforce by 20,000...
View ArticleHengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong...
Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China's leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars ($1.2 billion) from its proposed float on...
View ArticleBiohaven stock sinks on three-month delay for neuro drug's FDA approval decision
Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy troriluzole and will also require an advisory committee meeting to review the drug....
View ArticleMerck KGaA Q1 earnings: Tariff surcharge for US customers will continue
Despite pausing a tariff surcharge for China-based clients, Merck KGaA will carry on with adding an extra charge for US customers to account for President Donald Trump’s levies. “What we're doing is we...
View ArticleExclusive: Datavant will acquire Aetion, double life sciences team
The health tech company Datavant is acquiring Aetion, a rival in the real-world data space, Endpoints News exclusively reports. Datavant on Thursday plans to announce the deal, which will double the...
View ArticleAbundant Venture Partners teams up with 17 health systems to develop tech
Seventeen health systems have signed up for a venture firm to help them vet which health tech companies to adopt and invest in, as more hospitals look towards a more concierge-style approach to...
View Article
